Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Deflexifol for recurrent or refractory ependymoma in children and young adults
ACTRN12626000571370Phase 2Not yet recruiting
- Sponsor
- Australia & New Zealand Children’s Haematology and Oncology Group
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Deflexifol in ependymoma and central nervous system tumor, sponsored by Australia & New Zealand Children’s Haematology and Oncology Group. Primary endpoint: Overall response rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
Deflexifol
03
Conditions
ependymomacentral nervous system tumor
Beyond the preview
Go deeper on ACTRN12626000571370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000571370.